siponimod

Ligand id: 9289

Name: siponimod

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 3
Hydrogen bond donors 1
Rotatable bonds 10
Topological polar surface area 62.13
Molecular weight 516.26
XLogP 9.14
No. Lipinski's rules broken 1

Molecular properties generated using the CDK

Classification
Compound class Synthetic organic
IUPAC Name
1-[[4-[(E)-N-[[4-cyclohexyl-3-(trifluoromethyl)phenyl]methoxy]-C-methylcarbonimidoyl]-2-ethylphenyl]methyl]azetidine-3-carboxylic acid
International Nonproprietary Names
INN number INN
9491 siponimod
Synonyms
BAF-312 | BAF312 | compound 32 [PMID: 24900670]
Database Links
CAS Registry No. 1230487-00-9 (source: WHO INN record)
ChEMBL Ligand CHEMBL2336071
PubChem CID 44599207
Search Google for chemical match using the InChIKey KIHYPELVXPAIDH-HNSNBQBZSA-N
Search Google for chemicals with the same backbone KIHYPELVXPAIDH
Search PubMed clinical trials siponimod
Search PubMed titles siponimod
Search PubMed titles/abstracts siponimod
Search UniChem for chemical match using the InChIKey KIHYPELVXPAIDH-HNSNBQBZSA-N
Search UniChem for chemicals with the same backbone KIHYPELVXPAIDH
Comments
Siponimod (BAF312) is a Phase 3 clinical candidate being developed by Novartis for secondary progressive multiple sclerosis (SPMS), originally as a back-up compound for fingolimod. Pharmacologically, siponimod is a selective sphingosine-1-phosphate (S1P) receptor agonist [5] with improved pharmacokinetics compared to fingolimod.
Novartis announced positive results from their Phase 3 EXPAND study (BAF312 versus placebo) in SPMS (August 2016- link to announcement here).
The SIPR signalling pathway is important in autoimmune biology.